200 related articles for article (PubMed ID: 25641511)
21. Earlier effect of alendronate in mouse metaphyseal versus diaphyseal bone healing.
Sandberg O; Bernhardsson M; Aspenberg P
J Orthop Res; 2017 Apr; 35(4):793-799. PubMed ID: 27233101
[TBL] [Abstract][Full Text] [Related]
22. Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice.
Motyl KJ; McCabe LR
J Cell Physiol; 2009 Feb; 218(2):376-84. PubMed ID: 18932203
[TBL] [Abstract][Full Text] [Related]
23. The role of muscle loading on bone (Re)modeling at the developing enthesis.
Tatara AM; Lipner JH; Das R; Kim HM; Patel N; Ntouvali E; Silva MJ; Thomopoulos S
PLoS One; 2014; 9(5):e97375. PubMed ID: 24847982
[TBL] [Abstract][Full Text] [Related]
24. The influence of alendronate on bone formation and resorption in a rat ectopic bone development model.
Yaffe A; Kollerman R; Bahar H; Binderman I
J Periodontol; 2003 Jan; 74(1):44-50. PubMed ID: 12593595
[TBL] [Abstract][Full Text] [Related]
25. Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice.
Khorasani MS; Diko S; Hsia AW; Anderson MJ; Genetos DC; Haudenschild DR; Christiansen BA
Arthritis Res Ther; 2015 Feb; 17(1):30. PubMed ID: 25888819
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effects of high dietary calcium and exogenous parathyroid hormone in promoting osteoblastic bone formation in mice.
Feng Y; Zhou M; Zhang Q; Liu H; Xu Y; Shu L; Zhang J; Miao D; Ren Y
Br J Nutr; 2015 Mar; 113(6):909-22. PubMed ID: 25744000
[TBL] [Abstract][Full Text] [Related]
27. μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.
de Bakker CM; Altman AR; Tseng WJ; Tribble MB; Li C; Chandra A; Qin L; Liu XS
Bone; 2015 Apr; 73():198-207. PubMed ID: 25554598
[TBL] [Abstract][Full Text] [Related]
28. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity.
Kayal RA; Tsatsas D; Bauer MA; Allen B; Al-Sebaei MO; Kakar S; Leone CW; Morgan EF; Gerstenfeld LC; Einhorn TA; Graves DT
J Bone Miner Res; 2007 Apr; 22(4):560-8. PubMed ID: 17243865
[TBL] [Abstract][Full Text] [Related]
29. The effects of bisphosphonates on osteoblasts in vitro.
Naidu A; Dechow PC; Spears R; Wright JM; Kessler HP; Opperman LA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jul; 106(1):5-13. PubMed ID: 18504149
[TBL] [Abstract][Full Text] [Related]
30. Amylin and bone metabolism in streptozotocin-induced diabetic rats.
Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP
J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342
[TBL] [Abstract][Full Text] [Related]
31. Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse.
Lloyd SA; Travis ND; Lu T; Bateman TA
J Appl Physiol (1985); 2008 Mar; 104(3):729-38. PubMed ID: 18174391
[TBL] [Abstract][Full Text] [Related]
32. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
Komatsu K; Shimada A; Shibata T; Wada S; Ideno H; Nakashima K; Amizuka N; Noda M; Nifuji A
J Endocrinol; 2013 Nov; 219(2):145-58. PubMed ID: 24096963
[TBL] [Abstract][Full Text] [Related]
33. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells.
Panzavolta S; Torricelli P; Bracci B; Fini M; Bigi A
J Inorg Biochem; 2009 Jan; 103(1):101-6. PubMed ID: 18977031
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate inhibits bone turnover in OPG(-/-) mice via a depressive effect on both osteoclasts and osteoblasts.
Shoji S; Tabuchi M; Miyazawa K; Yabumoto T; Tanaka M; Kadota M; Maeda H; Goto S
Calcif Tissue Int; 2010 Aug; 87(2):181-92. PubMed ID: 20549197
[TBL] [Abstract][Full Text] [Related]
35. The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.
Gallagher EJ; Sun H; Kornhauser C; Tobin-Hess A; Epstein S; Yakar S; LeRoith D
Diabetes Metab Res Rev; 2014 Mar; 30(3):191-200. PubMed ID: 24023014
[TBL] [Abstract][Full Text] [Related]
36. Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells.
Chuguransky SR; Cortizo AM; McCarthy AD
Biomed Res Int; 2016; 2016():5891925. PubMed ID: 27840829
[TBL] [Abstract][Full Text] [Related]
37. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.
Botolin S; Faugere MC; Malluche H; Orth M; Meyer R; McCabe LR
Endocrinology; 2005 Aug; 146(8):3622-31. PubMed ID: 15905321
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition.
Patntirapong S; Singhatanadgit W; Chanruangvanit C; Lavanrattanakul K; Satravaha Y
J Oral Pathol Med; 2012 Oct; 41(9):713-20. PubMed ID: 22563819
[TBL] [Abstract][Full Text] [Related]
39. Anti-osteoporotic activity of harpagide by regulation of bone formation in osteoblast cell culture and ovariectomy-induced bone loss mouse models.
Chung HJ; Kyung Kim W; Joo Park H; Cho L; Kim MR; Kim MJ; Shin JS; Ho Lee J; Ha IH; Kook Lee S
J Ethnopharmacol; 2016 Feb; 179():66-75. PubMed ID: 26712566
[TBL] [Abstract][Full Text] [Related]
40. Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts.
Soydan SS; Araz K; Senel FV; Yurtcu E; Helvacioglu F; Dagdeviren A; Tekindal MA; Sahin F
Hum Exp Toxicol; 2015 Nov; 34(11):1073-82. PubMed ID: 25636638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
